177 related articles for article (PubMed ID: 25738681)
1. Atenolol versus Losartan in Marfan's Syndrome.
Ziganshin BA; Mukherjee SK; Elefteriades JA
N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681
[No Abstract] [Full Text] [Related]
2. Atenolol versus Losartan in Marfan's Syndrome.
Mallat Z; Tedgui A
N Engl J Med; 2015 Mar; 372(10):980. PubMed ID: 25738683
[No Abstract] [Full Text] [Related]
3. Atenolol versus Losartan in Marfan's Syndrome.
Treasure T; Pepper J; Mohiaddin R
N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682
[No Abstract] [Full Text] [Related]
4. Atenolol versus Losartan in Marfan's Syndrome.
Lacro RV; Dietz HC; Mahony L
N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680
[No Abstract] [Full Text] [Related]
5. Of Marfan's syndrome, mice, and medications.
Bowen JM; Connolly HM
N Engl J Med; 2014 Nov; 371(22):2127-8. PubMed ID: 25405389
[No Abstract] [Full Text] [Related]
6. Atenolol versus losartan in children and young adults with Marfan's syndrome.
Lacro RV; Dietz HC; Sleeper LA; Yetman AT; Bradley TJ; Colan SD; Pearson GD; Selamet Tierney ES; Levine JC; Atz AM; Benson DW; Braverman AC; Chen S; De Backer J; Gelb BD; Grossfeld PD; Klein GL; Lai WW; Liou A; Loeys BL; Markham LW; Olson AK; Paridon SM; Pemberton VL; Pierpont ME; Pyeritz RE; Radojewski E; Roman MJ; Sharkey AM; Stylianou MP; Wechsler SB; Young LT; Mahony L;
N Engl J Med; 2014 Nov; 371(22):2061-71. PubMed ID: 25405392
[TBL] [Abstract][Full Text] [Related]
7. [Drugs news].
Lengellé C; Bejan-Angoulvant T; Beau-Salinas F; Jonville-Béra AP
Arch Pediatr; 2015 Nov; 22(11):1200-6. PubMed ID: 26385645
[No Abstract] [Full Text] [Related]
8. Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al.
O'Rourke MF; Adji A; Weber T
Vasc Med; 2016 Feb; 21(1):70. PubMed ID: 26669325
[No Abstract] [Full Text] [Related]
9. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA
Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
Brooke BS; Habashi JP; Judge DP; Patel N; Loeys B; Dietz HC
N Engl J Med; 2008 Jun; 358(26):2787-95. PubMed ID: 18579813
[TBL] [Abstract][Full Text] [Related]
11. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
Sandor GG; Alghamdi MH; Raffin LA; Potts MT; Williams LD; Potts JE; Kiess M; van Breemen C
Int J Cardiol; 2015 Jan; 179():470-5. PubMed ID: 25465809
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.
Forteza A; Evangelista A; Sánchez V; Teixidó-Turà G; Sanz P; Gutiérrez L; Gracia T; Centeno J; Rodríguez-Palomares J; Rufilanchas JJ; Cortina J; Ferreira-González I; García-Dorado D
Eur Heart J; 2016 Mar; 37(12):978-85. PubMed ID: 26518245
[TBL] [Abstract][Full Text] [Related]
14. Medicine. Old drug, new hope for Marfan syndrome.
Travis J
Science; 2006 Apr; 312(5770):36-7. PubMed ID: 16601163
[No Abstract] [Full Text] [Related]
15. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
[TBL] [Abstract][Full Text] [Related]
16. [Recommendations for the medical management of aortic complications of Marfan's syndrome].
Jondeau G; Barthelet M; Baumann C; Bonnet D; Chevallier B; Collignon P; Dulac Y; Edouard T; Faivre L; Germain D; Khau Van Kien P; Lacombe D; Ladouceur M; Lemerrer M; Leheup B; Lupoglazoff JM; Magnier S; Muti C; Plauchu PH; Raffestin B; Sassolas F; Schleich JM; Sidi D; Themar-Noël C; Varin J; Wolf JE; ;
Arch Mal Coeur Vaiss; 2006 May; 99(5):540-6. PubMed ID: 16802751
[No Abstract] [Full Text] [Related]
17. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
[TBL] [Abstract][Full Text] [Related]
18. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
Mallat Z; Daugherty A
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
[No Abstract] [Full Text] [Related]
19. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
Habashi JP; Judge DP; Holm TM; Cohn RD; Loeys BL; Cooper TK; Myers L; Klein EC; Liu G; Calvi C; Podowski M; Neptune ER; Halushka MK; Bedja D; Gabrielson K; Rifkin DB; Carta L; Ramirez F; Huso DL; Dietz HC
Science; 2006 Apr; 312(5770):117-21. PubMed ID: 16601194
[TBL] [Abstract][Full Text] [Related]
20. Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis.
Li L; Yamani N; Al-Naimat S; Khurshid A; Usman MS
Eur J Prev Cardiol; 2020 Sep; 27(13):1447-1450. PubMed ID: 31260329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
